Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock

Understand Kiniksa Pharmaceuticals, Ltd.: how it makes money

Kiniksa sells ARCALYST, an IL-1 blocker injection for recurrent pericarditis, earning revenue from product sales to physicians and payers. It is a single-product commercial-stage biotech with pipeline candidates (Mavrilimumab, KPL-387) not expected to generate revenue before 2028.

ARCALYST's 90% gross margin is what keeps the lights on, but the 14% operating margin reveals that nearly every additional revenue dollar is absorbed by the expanding R&D, manufacturing, and commercial engine needed to build the next product.

Business quality (Solid): Solid

Valuation: At 97× earnings, KNSA trades 468% above the Pharmaceutical Products average (17×).

Bull case

• Prescriber base still wide open: ARCALYST added 450 new prescribers and 150 repeat prescribers in Q2 against an addressable base of more than 25,000 healthcare professionals nationally, meaning current penetration is early and the go-to-market runway extends well beyond the next several quarters.
• KPL-387 Phase 2 de-risks pipeline: Phase 2 data showed KPL-387 delivered a four-day median treatment and pain response, and market research indicated strong stated preference for a monthly dosing regimen, positioning it as a differentiated option in giant cell arteritis should Phase 3 go well.

Bear case

• Multiple prices in multi-product future: At a P/E of 97x versus a Pharmaceutical Products industry average of 17x (468% above), the valuation already assumes KPL-387 and other pipeline candidates will reach market and scale, not merely clear trials.
• Next revenue multiple years away: KPL-387's commercial launch is not expected until 2028 or 2029, leaving investors dependent on ARCALYST growth alone for the interim while the company executes a pivotal Phase 3 program.
• Expenses outpace single-product revenue: Management flagged that operating expenses are rising with clinical, manufacturing, commercial, and preclinical investment, a drag that holds operating margin at 14% even with a 90% gross margin on the product.

Kiniksa Pharmaceuticals, Ltd. earnings call transcripts

• KNSA Q2 FY26 earnings call transcript (reported 2026-07-28) · analysis
• KNSA Q4 FY25 earnings call transcript (reported 2026-02-24) · analysis

All KNSA earnings calls

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Ultragenyx Pharmaceutical Inc. (RARE)
• Supernus Pharmaceuticals, Inc. (SUPN)
• Amphastar Pharmaceuticals, Inc. (AMPH)
• Pacira BioSciences, Inc. (PCRX)
• Emergent BioSolutions Inc. (EBS)
• TG Therapeutics, Inc. (TGTX)
• OPKO Health, Inc. (OPK)
• Insmed Incorporated (INSM)